Published in J Clin Oncol on July 27, 2009
Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma. Eur Urol (2010) 3.20
Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma. Eur Urol (2014) 2.32
The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer. Ann Oncol (2011) 1.73
Percutaneous biopsy of primary tumor in metastatic renal cell carcinoma to predict high risk pathological features: comparison with nephrectomy assessment. J Urol (2010) 1.52
Renal cell carcinoma. BMJ (2014) 1.45
Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patients. Clin Cancer Res (2012) 1.44
Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma. J Clin Oncol (2010) 1.37
Treatment of metastatic renal cell carcinoma. Nat Rev Urol (2010) 1.24
Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma. J Urol (2010) 1.22
Early primary tumor size reduction is an independent predictor of improved overall survival in metastatic renal cell carcinoma patients treated with sunitinib. Eur Urol (2011) 1.13
Update on targeted therapies for clear cell renal cell carcinoma. Curr Opin Oncol (2011) 1.08
Gene and protein expression markers of response to combined antiangiogenic and epidermal growth factor targeted therapy in renal cell carcinoma. Ann Oncol (2010) 1.08
Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma. Oncogene (2015) 1.07
Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma. J Urol (2010) 1.04
Current status of targeted therapy for advanced renal cell carcinoma. Korean J Urol (2012) 1.02
High-resolution profiling of histone h3 lysine 36 trimethylation in metastatic renal cell carcinoma. Oncogene (2015) 1.01
Surgical management of renal cell carcinoma: Canadian Kidney Cancer Forum Consensus. Can Urol Assoc J (2014) 0.93
Response of renal lesions during systemic treatment with sunitinib in patients with metastatic renal cell carcinoma: a single center experience with 14 patients. World J Urol (2011) 0.90
Biomarkers: the next therapeutic hurdle in metastatic renal cell carcinoma. Br J Cancer (2012) 0.88
Differential microRNA expression in renal cell carcinoma. Oncol Lett (2013) 0.88
Recent updates in renal cell carcinoma. Curr Opin Oncol (2010) 0.88
Resection of metastasis and local recurrences of renal cell carcinoma after presurgical targeted therapy: probability of complete local control and outcome. World J Urol (2016) 0.87
Cytoreductive nephrectomy for metastatic RCC in the era of targeted therapy. Nat Rev Urol (2009) 0.87
Surgical management of metastatic renal cell carcinoma in the era of targeted therapies. World J Urol (2014) 0.85
Is there a role for neoadjuvant targeted therapy to downsize primary tumors for organ sparing strategies in renal cell carcinoma? Int J Surg Oncol (2012) 0.85
The role of neoadjuvant therapy in the management of locally advanced renal cell carcinoma. Ther Adv Urol (2015) 0.84
Targeted therapies in renal cell cancer: recent developments in imaging. Target Oncol (2010) 0.81
Adjuvant and neoadjuvant therapy in renal cell carcinoma. Curr Clin Pharmacol (2011) 0.80
Cytoreductive surgery in the era of targeted molecular therapy. Transl Androl Urol (2015) 0.78
The bevacizumab experience in advanced renal cell carcinoma. Onco Targets Ther (2010) 0.78
Presurgical therapy with axitinib for advanced renal cell carcinoma: a case report. BMC Res Notes (2013) 0.78
Transcription factor binding site analysis identifies FOXO transcription factors as regulators of the cutaneous wound healing process. PLoS One (2014) 0.78
Do targeted agents offer clinical benefit as presurgical therapy? World J Urol (2013) 0.76
The radiogenomic risk score stratifies outcomes in a renal cell cancer phase 2 clinical trial. Eur Radiol (2015) 0.76
Metastatic clear cell carcinoma of the kidney: therapeutic role of bevacizumab. Cancer Manag Res (2010) 0.75
Renal cell cancer: what can we learn from pre-operative studies? Front Oncol (2011) 0.75
Neo adjuvant treatment with targeted molecules for renal cell cancer in current clinical practise. Indian J Surg Oncol (2011) 0.75
Use of RENAL nephrometry scores for predicting tumor upgrading between core biopsies and surgical specimens: a prospective ex vivo study. Medicine (Baltimore) (2015) 0.75
Long-term management of patients with metastatic renal cell carcinoma on targeted agents. Expert Rev Anticancer Ther (2010) 0.75
Surgical Management of Advanced and Metastatic Renal Cell Carcinoma: A Multidisciplinary Approach. Front Oncol (2017) 0.75
Cancer statistics, 2007. CA Cancer J Clin (2007) 53.49
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med (2007) 39.39
Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med (2007) 30.94
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med (2007) 24.19
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet (2007) 15.92
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med (2003) 14.59
Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med (2001) 11.73
Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet (2001) 6.24
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol (2005) 4.64
Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol (2007) 3.26
Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol (1999) 2.45
Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. J Urol (2008) 2.45
Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm. BJU Int (2008) 2.35
Sunitinib for treatment of advanced renal cell cancer: primary tumor response. Clin Cancer Res (2008) 1.81
Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases. BMC Cancer (2008) 1.26
Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer. J Clin Oncol (2000) 1.26
The role of initial immunotherapy as selection for nephrectomy in patients with metastatic renal cell carcinoma and the primary tumor in situ. Eur Urol (2002) 0.99
Epigenetics in human disease and prospects for epigenetic therapy. Nature (2004) 11.46
Guideline for management of the clinical T1 renal mass. J Urol (2009) 8.26
Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med (2011) 5.82
A population of multipotent CD34-positive adipose stromal cells share pericyte and mesenchymal surface markers, reside in a periendothelial location, and stabilize endothelial networks. Circ Res (2007) 4.34
Reversal of obesity by targeted ablation of adipose tissue. Nat Med (2004) 4.23
PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther (2011) 4.22
Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol (2012) 3.92
Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. Am J Surg Pathol (2002) 3.52
Fingerprinting the circulating repertoire of antibodies from cancer patients. Nat Biotechnol (2002) 3.32
Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma. Eur Urol (2010) 3.20
Genetic basis for in vivo daptomycin resistance in enterococci. N Engl J Med (2011) 3.20
Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol (2005) 3.15
Intravascular delivery of particulate systems: does geometry really matter? Pharm Res (2008) 3.13
Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer (2009) 3.12
Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol (2004) 3.02
Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors. Nat Biotechnol (2003) 3.01
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00
Cell surface expression of the stress response chaperone GRP78 enables tumor targeting by circulating ligands. Cancer Cell (2004) 2.99
Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3. Nat Genet (2010) 2.96
Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood (2007) 2.91
Single-nucleotide polymorphisms inside microRNA target sites influence tumor susceptibility. Cancer Res (2010) 2.82
Secreted frizzled-related protein 1 loss contributes to tumor phenotype of clear cell renal cell carcinoma. Clin Cancer Res (2007) 2.77
Comparative analysis of laparoscopic versus open partial nephrectomy for renal tumors in 200 patients. J Urol (2003) 2.77
A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma. Eur Urol (2012) 2.77
Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy? Cancer (2010) 2.75
The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus. Eur Urol (2011) 2.72
Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life. Biol Blood Marrow Transplant (2011) 2.63
Focus on bladder cancer. Cancer Cell (2004) 2.59
Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res (2008) 2.59
Comparison of oncologic outcomes for open and laparoscopic nephroureterectomy: a multi-institutional analysis of 1249 cases. Eur Urol (2009) 2.55
Bladder cancer. J Natl Compr Canc Netw (2013) 2.46
Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. J Urol (2008) 2.45
Multimodality management of urachal carcinoma: the M. D. Anderson Cancer Center experience. J Urol (2003) 2.41
Safety of presurgical targeted therapy in the setting of metastatic renal cell carcinoma. Eur Urol (2011) 2.39
Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver. J Natl Cancer Inst (2008) 2.37
Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst (2009) 2.34
Distribution of cytokeratins and vimentin in adult renal neoplasms and normal renal tissue: potential utility of a cytokeratin antibody panel in the differential diagnosis of renal tumors. Am J Surg Pathol (2005) 2.32
Melanoma of the penis, scrotum and male urethra: a 40-year single institution experience. J Urol (2005) 2.25
Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens. J Natl Cancer Inst (2007) 2.24
Dose-finding with two agents in Phase I oncology trials. Biometrics (2003) 2.23
Body surface area and body weight predict total liver volume in Western adults. Liver Transpl (2002) 2.21
A hybrid vector for ligand-directed tumor targeting and molecular imaging. Cell (2006) 2.20
Assessment of the minimum number of lymph nodes needed to detect lymph node invasion at radical nephroureterectomy in patients with upper tract urothelial cancer. Urology (2009) 2.17
Mitochondrial DNA content: its genetic heritability and association with renal cell carcinoma. J Natl Cancer Inst (2008) 2.17
Prognostic factors in upper urinary tract urothelial carcinomas: a comprehensive review of the current literature. Eur Urol (2012) 2.17
Micropapillary component in lung adenocarcinoma: a distinctive histologic feature with possible prognostic significance. Am J Surg Pathol (2002) 2.15
Obesity, weight gain, and risk of biochemical failure among prostate cancer patients following prostatectomy. Clin Cancer Res (2005) 2.14
Extraosseous osteosarcoma: response to treatment and long-term outcome. J Clin Oncol (2002) 2.13
Three-dimensional tissue culture based on magnetic cell levitation. Nat Nanotechnol (2010) 2.11
Single nucleotide polymorphisms of microRNA machinery genes modify the risk of renal cell carcinoma. Clin Cancer Res (2008) 2.11
The crosstalk of mTOR/S6K1 and Hedgehog pathways. Cancer Cell (2012) 2.02
Follow-up guidelines after radical or partial nephrectomy for localized and locally advanced renal cell carcinoma. Can Urol Assoc J (2009) 2.00
Novel therapies for metastatic castrate-resistant prostate cancer. J Natl Cancer Inst (2011) 1.98
Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. Biol Blood Marrow Transplant (2008) 1.96
Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia. Blood (2014) 1.95
Bayesian and frequentist two-stage treatment strategies based on sequential failure times subject to interval censoring. Stat Med (2007) 1.92
Display technologies: application for the discovery of drug and gene delivery agents. Adv Drug Deliv Rev (2006) 1.92
Tumour necrosis is an indicator of aggressive biology in patients with urothelial carcinoma of the upper urinary tract. Eur Urol (2009) 1.92
Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the M. D. Anderson cancer experience. J Urol (2004) 1.91
Adjuvant chemotherapy for high risk upper tract urothelial carcinoma: results from the Upper Tract Urothelial Carcinoma Collaboration. J Urol (2009) 1.90
Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer (2007) 1.83
Illness uncertainty and quality of life of patients with small renal tumors undergoing watchful waiting: a 2-year prospective study. Eur Urol (2013) 1.81
Bilateral testicular germ cell tumors: twenty-year experience at M. D. Anderson Cancer Center. Cancer (2002) 1.81
Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol (2002) 1.79
White adipose tissue cells are recruited by experimental tumors and promote cancer progression in mouse models. Cancer Res (2009) 1.78
The extent of lymphadenectomy seems to be associated with better survival in patients with nonmetastatic upper-tract urothelial carcinoma: how many lymph nodes should be removed? Eur Urol (2009) 1.78
Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes. Leuk Lymphoma (2014) 1.77
High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation. Transplantation (2009) 1.76
Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells. Cancer Res (2002) 1.76
Patient survival after surgery for osseous metastases from renal cell carcinoma. J Bone Joint Surg Am (2007) 1.75
State of the art. Cellular and molecular mechanisms of alveolar destruction in emphysema: an evolutionary perspective. Proc Am Thorac Soc (2006) 1.75
Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood (2011) 1.75
Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clin Cancer Res (2007) 1.74